VIA EDGAR
May 25, 2021
Office of Life Sciences
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Attn: Irene Paik, Joe McCann, Tara Harkins and Dan Gordon
| Re: | Centessa Pharmaceuticals plc | |||
| Acceleration Request for Registration Statement on Form S-1 | ||||
| File No. 333-255393 | ||||
| Requested Date: | May 27, 2021 | |||
| Requested Time: | 4:00 p.m. Eastern Time | |||
Ladies and Gentlemen:
Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, we wish to advise that as of the date hereof, approximately 3,878 copies of the Preliminary Prospectus dated May 24, 2021 were distributed to prospective underwriters, institutional investors and prospective dealers in connection with the above captioned Registration Statement.
We wish to advise you that the participating underwriters have informed us that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
We hereby join in the request of the registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Time, on May 27, 2021 or as soon thereafter as practicable.
[Signature page follows]
Very truly yours,
MORGAN STANLEY & CO. LLC
GOLDMAN SACHS & CO. LLC
JEFFERIES LLC
EVERCORE GROUP L.L.C.
As representatives of the Underwriters
MORGAN STANLEY & CO. LLC
| By: | /s/ Chirag D. Surti | |
| Name: Chirag D. Surti | ||
| Title: Vice President | ||
| GOLDMAN SACHS & CO. LLC | ||
| By: | /s/ Elizabeth Reed | |
| Name: Elizabeth Reed | ||
| Title: Managing Director | ||
| JEFFERIES LLC | ||
| By: | /s/ Matthew Kim | |
| Name: Matthew Kim | ||
| Title: Managing Director, Joint US Head of Biopharmaceuticals | ||
| EVERCORE GROUP L.L.C. | ||
| By: | /s/ Francois Maisonrouge | |
| Name: Francois Maisonrouge | ||
| Title: Senior Managing Director | ||
[Signature Page to Acceleration Request]